Patents by Inventor Jens Juul Holst

Jens Juul Holst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptide dual agonists of GIPR and GLP2R
    Patent number: 11725037
    Abstract: Provided herewith are peptide dual agonists of at least the GIPR (glucose-dependent insulinotropic polypeptide receptor) and the GLP2R (glucagon-like peptide-2 receptor), and their use for treatment of bone disorders such as osteoporosis.
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: August 15, 2023
    Assignee: University of Copenhagen
    Inventors: Bolette Hartmann, Maria Buur Nordskov Gabe, Lærke Smidt Gasbjerg, Mette Marie Rosenkilde, Jens Juul Holst
  • Long-acting GIP peptide analogues
    Patent number: 11572399
    Abstract: Disclosed are glucose-dependent insulinotropic peptide (GIP)-derived peptide analogues GIPS-30 and GIP3-30 which are antagonists of the GIP receptor and comprises at least one fatty acid molecule to increase half-life while maintaining antagonistic properties.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: February 7, 2023
    Assignee: UNIVERSITY OF COPENHAGEN
    Inventors: Mette Marie Rosenkilde, Jens Juul Holst, Lærke Smidt Gasbjerg, Alexander Hovard Sparre-Ulrich, Maria Buur Nordskov Gabe
  • GIP PEPTIDE ANALOGUES
    Publication number: 20210340211
    Abstract: Provided herein are glucose-dependent insulinotropic polypeptide (GIP)-derived peptide analogues, for example GIP(3-30), and their use as antagonists of the GIP receptor and for treatment of disorders such as obesity, diabetes mellitus and insulin resistance.
    Type: Application
    Filed: March 1, 2021
    Publication date: November 4, 2021
    Inventors: Alexander Hovard Sparre-Ulrich, Mette Marie Rosenkilde, Jens Juul Holst, Filip Krag Knop, Mikkel Bring Christensen, Laerke Smidt Gasbjerg
  • GIP peptide analogues
    Patent number: 10968266
    Abstract: Provided herein are glucose-dependent insulinotropic polypeptide (GIP)-derived peptide analogues, for example GIP(3-30), and their use as antagonists of the GIP receptor and for treatment of disorders such as obesity, diabetes mellitus and insulin resistance.
    Type: Grant
    Filed: September 7, 2015
    Date of Patent: April 6, 2021
    Assignee: UNIVERSITY OF COPENHAGEN
    Inventors: Alexander Hovard Sparre-Ulrich, Mette Marie Rosenkilde, Jens Juul Holst, Filip Krag Knop, Mikkel Bring Christensen, Lærke Smidt Gasbjerg
  • PEPTIDE DUAL AGONISTS OF GIPR AND GLP2R
    Publication number: 20200392198
    Abstract: Provided herewith are peptide dual agonists of at least the GIPR (glucose-dependent insulinotropic polypeptide receptor) and the GLP2R (glucagon-like peptide-2 receptor), and their use for treatment of bone disorders such as osteoporosis.
    Type: Application
    Filed: August 31, 2020
    Publication date: December 17, 2020
    Inventors: Bolette Hartmann, Maria Buur Nordskov Gabe, Lærke Smidt Gasbjerg, Mette Marie Rosenkilde, Jens Juul Holst
  • Peptide dual agonists of GIPR and GLP2R
    Patent number: 10774127
    Abstract: Provided herewith are peptide dual agonists of at least the GIPR (glucose-dependent insulinotropic polypeptide receptor) and the GLP2R (glucagon-like peptide-2 receptor), and their use for treatment of bone disorders such as osteoporosis.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: September 15, 2020
    Assignee: University of Copenhagen
    Inventors: Bolette Hartmann, Maria Buur Nordskov Gabe, Lærke Smidt Gasbjerg, Mette Marie Rosenkilde, Jens Juul Holst
  • COMBINATION THERAPY FOR TREATMENT OF BONE DISORDERS
    Publication number: 20200261543
    Abstract: Provided herewith is the use of glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-2 (GLP-2) for treatment of bone disorders such as osteoporosis.
    Type: Application
    Filed: October 11, 2018
    Publication date: August 20, 2020
    Inventors: Bolette Hartmann, Maria Buur Nordskov Gabe, Lærke Smidt Gasbjerg, Mette Marie Rosenkilde, Jens Juul Holst, Kirsa Skov-Jeppesen
  • LONG-ACTING GIP PEPTIDE ANALOGUES
    Publication number: 20200087373
    Abstract: Disclosed are glucose-dependent insulinotropic peptide (GIP)-derived peptide analogues GIP5-30 and GIP3-30 which are antagonists of the GIP receptor and comprises at least one fatty acid molecule to increase half-life while maintaining antagonistic properties.
    Type: Application
    Filed: May 31, 2018
    Publication date: March 19, 2020
    Inventors: Mette Marie Rosenkilde, Jens Juul Holst, Lærke Smidt Gasbjerg, Alexander Hovard Sparre-Ulrich, Maria Buur Nordskov Gabe
  • PEPTIDE DUAL AGONISTS OF GIPR AND GLP2R
    Publication number: 20190389924
    Abstract: Provided herewith are peptide dual agonists of at least the GIPR (glucose-dependent insulinotropic polypeptide receptor) and the GLP2R (glucagon-like peptide-2 receptor), and their use for treatment of bone disorders such as osteoporosis.
    Type: Application
    Filed: October 12, 2017
    Publication date: December 26, 2019
    Inventors: Bolette Hartmann, Maria Buur Nordskov Gabe, Lærke Smidt Gasbjerg, Mette Marie Rosenkilde, Jens Juul Holst
  • GIP PEPTIDE ANALOGUES
    Publication number: 20180258152
    Abstract: Provided herein are glucose-dependent insulinotropic polypeptide (GIP)-derived peptide analogues, for example GIP(3-30), and their use as antagonists of the GIP receptor and for treatment of disorders such as obesity, diabetes mellitus and insulin resistance.
    Type: Application
    Filed: September 7, 2015
    Publication date: September 13, 2018
    Applicant: University of Copenhagen
    Inventors: Alexander Hovard Sparre-Ulrich, Mette Marie Rosenkilde, Jens Juul Holst, Filip Krag Knop, Mikkel Bring Christensen, Lærke Smidt Gasbjerg
  • TREATMENT OF INSULIN RESISTANCE AND OBESITY BY STIMULATING GLP-1 RELEASE
    Publication number: 20120128770
    Abstract: The present invention relates to 1 or 2 C16-C18 acyl glycerol based compounds which are capable of activating G-protein coupled receptor 119 and thereby stimulate GLP-1 release. Compounds of the present invention are useful in the prophylaxis and/or treatment of metabolic disorders and complications thereof, such as, type 2 diabetes mellitus (T2DM), obesity, insulin resistance, and cardiovascular disease.
    Type: Application
    Filed: June 24, 2010
    Publication date: May 24, 2012
    Applicant: Kobenhavns Universitet
    Inventors: Harald S. Hansen, Thi Ai Diep, Jens Juul Holst, Mette Marie Rosenkilde, Niels Wellner Andersen
  • Use of GLP-1 Peptides
    Publication number: 20110028391
    Abstract: GLP-1(1-45) or a fragment or an analogue thereof can be used in the preparation of a medicament for peripheral administration in the suppression of appetite or induction of satiety.
    Type: Application
    Filed: October 15, 2010
    Publication date: February 3, 2011
    Applicant: Novo Nordisk A/S
    Inventors: Jens Juul Holst, Arne Vernon Astrup, Martin Edward Judge, Liselotte Bjerre Knudsen, Lars Thim, Birgitte Schjellerup Wulff
  • Use of GLP-1 Peptides
    Publication number: 20100113363
    Abstract: GLP-1(1-45) or a fragment or an analogue thereof can be used in the preparation of a medicament for peripheral administration in the suppression of appetite or induction of satiety.
    Type: Application
    Filed: January 4, 2010
    Publication date: May 6, 2010
    Applicant: Novo Nordisk A/S
    Inventors: Jens Juul Holst, Arne Vernon Astrup, Martin Edward Judge, Liselotte Bjerre Knudsen, Lars Thim, Birgitte Schjellerup Wulff
  • Use of GLP-1 Peptides
    Publication number: 20090149387
    Abstract: GLP-1(1-45) or a fragment or an analogue thereof can be used in the preparation of a medicament for peripheral administration in the suppression of appetite or induction of satiety.
    Type: Application
    Filed: February 12, 2009
    Publication date: June 11, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Jens Juul Holst, Arne Vernon Astrup, Martin Edward Judge, Liselotte Bjerre Knudsen, Lars Thim, Birgitte Schjellerup Wulff
  • Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
    Patent number: 7371721
    Abstract: The present invention relates to methods for prevention and treatment of bone-related disorders and calcium homeostasis related syndromes using a GLP-2 molecule or GLP-2 activator either alone or in combination with another therapeutic. The present invention also encompasses methods of diagnosing or monitoring the progression of a disorder. The invention also encompasses methods of monitoring the effectiveness of treatment of the invention.
    Type: Grant
    Filed: January 14, 2005
    Date of Patent: May 13, 2008
    Assignee: Sanos Bioscience A/S
    Inventors: Dennis Bang Henriksen, Jens Juul Holst
  • Use of GLP-1 peptides
    Publication number: 20030232754
    Abstract: GLP-1(1-45) or a fragment or an analogue thereof can be used in the preparation of a medicament for peripheral administration in the suppression of appetite or induction of satiety.
    Type: Application
    Filed: March 6, 2003
    Publication date: December 18, 2003
    Inventors: Jens Juul Holst, Arne Vernon Astrup, Martin Edward Judge, Liselotte Bjerre Knudsen, Lars Thim, Birgitte Schjellerup Wulff
  • Use of a pharmaceutical composition comprising an appetite-suppressing peptide
    Patent number: 5912229
    Abstract: The present invention relates to appetite-suppressing peptides or an appetite-suppressing peptide-containing fraction for the treatment of obesity or type II diabetes.
    Type: Grant
    Filed: February 28, 1997
    Date of Patent: June 15, 1999
    Assignee: Novo Nordisk Als
    Inventors: Lars Thim, Birgitte Schjellerup Wulff, Martin Edward Judge, Ole Dragsbaek Madsen, Jens Juul Holst